{"id":"W2897300072","doi":"10.1093/annonc/mdy283.080","title":"KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Internal medicine; Clear cell renal cell carcinoma; Clinical endpoint; Oncology; Renal cell carcinoma; Progressive disease; Response Evaluation Criteria in Solid Tumors; Surgery; Urology; Chemotherapy; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002060003,0.0009250825,0.001143012,0.0003847644,0.0006932463,0.001024458,0.001112221,0.0008670894,0.009953931],"category_scores_gemma":[0.001277267,0.0003897861,0.0009120374,0.0005345579,0.0003967001,0.0007865794,0.0006015282,0.001705744,0.0018902],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001197504,"about_ca_system_score_gemma":0.002860303,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002277005,"about_ca_topic_score_gemma":0.005983679,"domain_scores_codex":[0.9993767,0.0002240602,0.00004635572,0.0001255067,0.0001295314,0.00009786776],"domain_scores_gemma":[0.9988374,0.0001329842,0.000234159,0.0001454822,0.0001803975,0.0004695408],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6573263,0.04002977,0.07017788,0.002944759,0.003012022,0.0009491839,0.0004008802,0.0034129,0.04530676,0.0009544991,0.0655204,0.1099646],"study_design_scores_gemma":[0.5944975,0.2066448,0.1250973,0.0003433661,0.002558719,0.001944009,0.0002332719,0.002533969,0.0140217,0.0005922957,0.05141735,0.0001157041],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9326348,0.003634398,0.001376753,0.0007524541,0.0002070569,0.01185277,0.04081564,0.0001698003,0.008556333],"genre_scores_gemma":[0.900297,0.002711455,0.004109978,0.002179043,0.0005272815,0.01041199,0.07153361,0.00008055836,0.008149056],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009953931,"threshold_uncertainty_score":0.03329927,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05574008702059895,"score_gpt":0.3487237175352484,"score_spread":0.2929836305146494,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}